The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. Current management of classic HL involves initial treatment with chemotherapy alone or combined modality therapy followed by restaging with PET/CT to assess treatment response. Overall, the introduction of less toxic and more effective regimens has significantly advanced HL cure rates. This portion of the NCCN Guidelines focuses on the management of classic HL.
Individual Disclosures for the NCCN Hodgkin Lymphoma Panel
El-GalalyT, MylamKJ, BrownP, et al.. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs. Haematologica2012;97:931–936.
El-GalalyT, MylamKJ, BrownP, . Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs. Haematologica 2012;97:931–936.10.3324/haematol.2011.05601022207683)| false
El-GalalyTC, MylamKJ, BøgstedM, et al.. Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol2014;89:575–580.
El-GalalyTC, MylamKJ, BøgstedM, . Role of routine imaging in detecting recurrent lymphoma: a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol 2014;89:575–580.2449338910.1002/ajh.23688)| false
GandikotaN, Hartridge-LambertS, MigliacciJC, et al.. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy. Cancer2015;121:1985–1992.
GandikotaN, Hartridge-LambertS, MigliacciJC, . Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy. Cancer 2015;121:1985–1992.10.1002/cncr.2927725739719)| false
MocikovaH, ObrtlikovaP, VackovaB, et al.. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol2010;21:1222–1227.
MocikovaH, ObrtlikovaP, VackovaB, . Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol 2010;21:1222–1227.10.1093/annonc/mdp52219901011)| false
El-GalalyTC, d’AmoreF, MylamKJ, et al.. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol2012;30:4508–4514.
El-GalalyTC, d’AmoreF, MylamKJ, . Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012;30:4508–4514.10.1200/JCO.2012.42.403623150698)| false
SalaunPY, GastinneT, Bodet-MilinC, et al.. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation?Eur J Nucl Med Mol Imaging2009;36:1813–1821.
SalaunPY, GastinneT, Bodet-MilinC, . Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin’s lymphoma: a reflection of disease infiltration or just inflammation?Eur J Nucl Med Mol Imaging 2009;36:1813–1821.10.1007/s00259-009-1183-019499219)| false
Moulin-RomseeG, HindiéE, CuencaX, et al.. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging2010;37:1095–1105.
Moulin-RomseeG, HindiéE, CuencaX, . (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010;37:1095–1105.10.1007/s00259-009-1377-520204358)| false
KumarA, CasuloC, YahalomJ, et al.. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood2016;128:1458–1464.
KumarA, CasuloC, YahalomJ, . Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood 2016;128:1458–1464.2745800310.1182/blood-2016-03-703470)| false
StrausDJ, PortlockCS, QinJ, et al.. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood2004;104:3483–3489.
StrausDJ, PortlockCS, QinJ, . Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483–3489.10.1182/blood-2004-04-131115315964)| false
van der KaaijMA, HeutteN, MeijndersP, et al.. Premature ovarian failure and fertility in long-term survivors of Hodgkin’s lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d’Etude des Lymphomes de l’Adulte Cohort Study. J Clin Oncol2012;30:291–299.
van der KaaijMA, HeutteN, MeijndersP, . Premature ovarian failure and fertility in long-term survivors of Hodgkin’s lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d’Etude des Lymphomes de l’Adulte Cohort Study. J Clin Oncol 2012;30:291–299.10.1200/JCO.2011.37.1989)| false
SieniawskiM, ReinekeT, NogovaL, et al.. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood2008;111:71–76.
SieniawskiM, ReinekeT, NogovaL, . Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008;111:71–76.10.1182/blood-2007-02-073544)| false
van der KaaijMA, van Echten-ArendsJ, SimonsAH, . Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 2010;28:168–179.10.1002/hon.939)| false
ChesonBD, FisherRI, BarringtonSF, et al.. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol2014;32:3059–3067.
ChesonBD, FisherRI, BarringtonSF, . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059–3067.2511375310.1200/JCO.2013.54.8800)| false
MauchP, GoodmanR, HellmanS. The significance of mediastinal involvement in early stage Hodgkin’s disease. Cancer 1978;42:1039–1045.10.1002/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R698907)| false
ListerTA, CrowtherD, SutcliffeSB, et al.. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol1989;7:1630–1636.
ListerTA, CrowtherD, SutcliffeSB, . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.10.1200/JCO.1989.7.11.16302809679)| false
Henry-AmarM, FriedmanS, HayatM, et al.. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. Ann Intern Med1991;114:361–365.
Henry-AmarM, FriedmanS, HayatM, . Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. Ann Intern Med 1991;114:361–365.199287710.7326/0003-4819-114-5-361)| false
TubianaM, Henry-AmarM, HayatM, et al.. Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer1984;54:885–894.
TubianaM, Henry-AmarM, HayatM, . Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer 1984;54:885–894.10.1002/1097-0142(19840901)54:5<885::AID-CNCR2820540522>3.0.CO;2-B6378359)| false
HasencleverD, DiehlV, ArmitageJO, . A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998;339:1506–1514.981944910.1056/NEJM199811193392104)| false
MocciaAA, DonaldsonJ, ChhanabhaiM, et al.. International Prognostic Score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol2012;30:3383–3388.
MocciaAA, DonaldsonJ, ChhanabhaiM, . International Prognostic Score in advanced-stage Hodgkin’s lymphoma: altered utility in the modern era. J Clin Oncol 2012;30:3383–3388.2286988710.1200/JCO.2011.41.0910)| false
BarringtonSF, MikhaeelNG, KostakogluL, et al.. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol2014;32:3048–3058.
BarringtonSF, MikhaeelNG, KostakogluL, . Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32:3048–3058.10.1200/JCO.2013.53.5229)| false
IsasiCR, LuP, BlaufoxMD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer2005;104:1066–1074.
IsasiCR, LuP, BlaufoxMD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:1066–1074.1604733510.1002/cncr.21253)| false
de WitM, BohuslavizkiKH, BuchertR, et al.. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol2001;12:29–37.
de WitM, BohuslavizkiKH, BuchertR, . 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol 2001;12:29–37.10.1023/A:1008357126404)| false
GuayC, LépineM, VerreaultJ, et al.. Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evaluation. J Nucl Med2003;44:1225–1231.
GuayC, LépineM, VerreaultJ, . Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evaluation. J Nucl Med 2003;44:1225–1231.12902411)| false
SherDJ, MauchPM, Van Den AbbeeleA, et al.. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved-field radiotherapy. Ann Oncol2009;20:1848–1853.
SherDJ, MauchPM, Van Den AbbeeleA, . Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009;20:1848–1853.10.1093/annonc/mdp07119541793)| false
MeignanM, GallaminiA, HaiounC, et al.. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma2010;51:2171–2180.
MeignanM, GallaminiA, HaiounC, . Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010;51:2171–2180.2107773710.3109/10428194.2010.529208)| false
MeignanM, GallaminiA, IttiE, et al.. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma2012;53:1876–1881.
MeignanM, GallaminiA, IttiE, . Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 2012;53:1876–1881.10.3109/10428194.2012.67753522432519)| false
BarringtonSF, QianW, SomerEJ, et al.. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging2010;37:1824–1833.
BarringtonSF, QianW, SomerEJ, . Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37:1824–1833.10.1007/s00259-010-1490-520505930)| false
BarringtonSF, KlugeR. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging 2017; 44(S1, Suppl 1)97–110.10.1007/s00259-017-3690-828411336)| false
SchaeferNG, TavernaC, StrobelK, et al.. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?Radiology2007;244:257–262.
SchaeferNG, TavernaC, StrobelK, . Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?Radiology 2007;244:257–262.1758190510.1148/radiol.2441060810)| false
BarringtonSF, KirkwoodAA, FranceschettoA, et al.. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood2016;127:1531–1538.
BarringtonSF, KirkwoodAA, FranceschettoA, . PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. Blood 2016;127:1531–1538.10.1182/blood-2015-11-67940726747247)| false
BiggiA, GallaminiA, ChauvieS, et al.. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med2013;54:683–690.
BiggiA, GallaminiA, ChauvieS, . International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013;54:683–690.10.2967/jnumed.112.11089023516309)| false
GallaminiA, BarringtonSF, BiggiA, et al.. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica2014;99:1107–1113.
GallaminiA, BarringtonSF, BiggiA, . The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 2014;99:1107–1113.10.3324/haematol.2013.10321824658820)| false
GallaminiA, KostakogluL. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials?Blood 2012;120:4913–4920.10.1182/blood-2012-03-40379022932799)| false
RadfordJ, IllidgeT, CounsellN, . Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 2015;372:1598–1607.2590142610.1056/NEJMoa1408648)| false
AldinA, UmlauffL, EstcourtLJ, et al.. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev2019;9:CD012643.
AldinA, UmlauffL, EstcourtLJ, . Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. Cochrane Database Syst Rev 2019;9:CD012643.31525824)| false
KobeC, GoergenH, BauesC, . Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma. Blood 2018;132:2273–2279.3016632910.1182/blood-2018-05-852129)| false
AndréMPE, GirinskyT, FedericoM, et al.. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol2017;35:1786–1794.
AndréMPE, GirinskyT, FedericoM, . Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2017;35:1786–1794.10.1200/JCO.2016.68.6394)| false
JohnsonP, FedericoM, KirkwoodA, et al.. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med2016;374:2419–2429.
GallaminiA, HutchingsM, AvigdorA, . Early interim PET scan in Hodgkin lymphoma: where do we stand?Leuk Lymphoma 2008;49:659–662.1839873210.1080/10428190801888704)| false
TerasawaT, LauJ, BardetS, et al.. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol2009;27:1906–1914.
LynchRC, AdvaniRH. Risk-adapted treatment of advanced Hodgkin lymphoma with PET-CT. Am Soc Clin Oncol Educ Book 2016;35:e376–e385.10.14694/EDBK_15903627249744)| false
DabajaBS, HoppeBS, PlastarasJP, et al.. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood2018;132:1635–1646; erratum in: Blood 2019;133:1385–1385.
DabajaBS, HoppeBS, PlastarasJP, . Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood 2018;132:1635–1646; erratum in: Blood 2019;133:1385–1385.3010806610.1182/blood-2018-03-837633)| false
LiJ, DabajaB, ReedV, et al.. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys2011;81:167–174.
LiJ, DabajaB, ReedV, . Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys 2011;81:167–174.2064351810.1016/j.ijrobp.2010.05.007)| false
HoppeBS, FlampouriS, SuZ, et al.. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys2012;84:449–455.
HoppeBS, FlampouriS, SuZ, . Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012;84:449–455.2238637310.1016/j.ijrobp.2011.12.034)| false
GirinskyT, PichenotC, BeaudreA, et al.. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?Int J Radiat Oncol Biol Phys2006;64:218–226.
GirinskyT, PichenotC, BeaudreA, . Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?Int J Radiat Oncol Biol Phys 2006;64:218–226.)| false
NiederC, SchillS, KneschaurekP, et al.. Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol2007;2:20.
NiederC, SchillS, KneschaurekP, . Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol 2007;2:20.10.1186/1748-717X-2-2017547777)| false
PaumierA, GhalibafianM, GilmoreJ, et al.. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys2012;82:1522–1527.
PaumierA, GhalibafianM, GilmoreJ, . Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 2012;82:1522–1527.10.1016/j.ijrobp.2011.05.01521705151)| false
FilippiAR, RagonaR, FusellaM, et al.. Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Pract Radiat Oncol2013;3:216–222.
FilippiAR, RagonaR, FusellaM, . Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Pract Radiat Oncol 2013;3:216–222.2467436710.1016/j.prro.2012.12.006)| false
CharpentierA-M, ConradT, SykesJ, et al.. Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose. Pract Radiat Oncol2014;4:174–180.
CharpentierA-M, ConradT, SykesJ, . Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose. Pract Radiat Oncol 2014;4:174–180.10.1016/j.prro.2013.07.01524766684)| false
FilippiAR, CiammellaP, PivaC, et al.. Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. Int J Radiat Oncol Biol Phys2014;89:370–375.
VoongKR, McSpaddenK, PinnixCC, et al.. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol2014;9:94.
VoongKR, McSpaddenK, PinnixCC, . Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol 2014;9:94.10.1186/1748-717X-9-9424735767)| false
GirinskyT, van der MaazenR, SpechtL, et al.. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol2006;79:270–277.
GirinskyT, van der MaazenR, SpechtL, . Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006;79:270–277.1679775510.1016/j.radonc.2006.05.015)| false
PaumierA, GhalibafianM, BeaudreA, et al.. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys2011;80:199–205.
PaumierA, GhalibafianM, BeaudreA, . Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011;80:199–205.2148172310.1016/j.ijrobp.2010.09.007)| false
SpechtL, YahalomJ, IllidgeT, et al..ILROG. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys2014;89:854–862.
SpechtL, YahalomJ, IllidgeT, .ILROG. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014;89:854–862.10.1016/j.ijrobp.2013.05.00523790512)| false
HoskinPJ, DíezP, WilliamsM, . Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol (R Coll Radiol) 2013;25:49–58.10.1016/j.clon.2012.07.01122889569)| false
GrégoireV, MackieTR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer Radiother2011;15:555–559.
GrégoireV, MackieTR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). Cancer Radiother 2011;15:555–559.10.1016/j.canrad.2011.04.00321802333)| false
AdvaniRH, HoppeRT, BaerD, et al.. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol2013;24:1044–1048.
AdvaniRH, HoppeRT, BaerD, . Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol 2013;24:1044–1048.10.1093/annonc/mds542)| false
EngertA, PlütschowA, EichHT, . Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010;363:640–652.10.1056/NEJMoa100006720818855)| false
DühmkeE, FranklinJ, PfreundschuhM, et al.. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol2001;19:2905–2914.
DühmkeE, FranklinJ, PfreundschuhM, . Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001;19:2905–2914.1138736410.1200/JCO.2001.19.11.2905)| false
FuchsM, GoergenH, KobeC, et al.. Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol2019;37:2835–2845.
FuchsM, GoergenH, KobeC, . Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol 2019;37:2835–2845.10.1200/JCO.19.00964)| false
StrausDJ, JungSH, PitcherB, et al.. CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood2018;132:1013–1021.
AdvaniRH, HongF, FisherRI, et al.. Randomized phase III trial comparing ABVD plus radiotherapy with the stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. J Clin Oncol2015;33:1936–1942.
AdvaniRH, HongF, FisherRI, . Randomized phase III trial comparing ABVD plus radiotherapy with the stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial. J Clin Oncol 2015;33:1936–1942.10.1200/JCO.2014.57.8138)| false
GordonLI, HongF, FisherRI, et al.. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol2013;31:684–691.
GordonLI, HongF, FisherRI, . Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684–691.10.1200/JCO.2012.43.4803)| false
von TresckowB, PlütschowA, FuchsM, et al.. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol2012;30:907–913.
von TresckowB, PlütschowA, FuchsM, . Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012;30:907–913.10.1200/JCO.2011.38.5807)| false
CanellosGP, AndersonJR, PropertKJ, et al.. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med1992;327:1478–1484.
CanellosGP, AndersonJR, PropertKJ, . Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.138382110.1056/NEJM199211193272102)| false
MerliF, LuminariS, GobbiPG, et al.. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol2016;34:1175–1181.
MerliF, LuminariS, GobbiPG, . Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol 2016;34:1175–1181.10.1200/JCO.2015.62.481726712220)| false
VivianiS, ZinzaniPL, RambaldiA, . ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203–212.10.1056/NEJMoa110034021774708)| false
PressOW, LiH, SchöderH, et al.. US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol2016;34:2020–2027.
PressOW, LiH, SchöderH, . US Intergroup Trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol 2016;34:2020–2027.10.1200/JCO.2015.63.1119)| false
StephensDM, LiH, SchöderH, et al.. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood2019;134:1238–1246.
StephensDM, LiH, SchöderH, . Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 2019;134:1238–1246.3133191810.1182/blood.2019000719)| false
GallaminiA, TarellaC, VivianiS, et al.. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: Long-term results of the GITIL/FIL HD 0607 Trial. J Clin Oncol2018;36:454–462.
GallaminiA, TarellaC, VivianiS, . Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: Long-term results of the GITIL/FIL HD 0607 Trial. J Clin Oncol 2018;36:454–462.29360414)| false
BorchmannP, HaverkampH, DiehlV, et al.. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol2011;29:4234–4242.
BorchmannP, HaverkampH, DiehlV, . Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 2011;29:4234–4242.)| false
EngertA, DiehlV, FranklinJ, et al.. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol2009;27:4548–4554.
EngertA, DiehlV, FranklinJ, . Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548–4554.1970406810.1200/JCO.2008.19.8820)| false
KrizJ, ReinartzG, DietleinM, et al.. Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys2015;92:46–53.
KrizJ, ReinartzG, DietleinM, . Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2015;92:46–53.10.1016/j.ijrobp.2015.01.048)| false
BorchmannP, GoergenH, KobeC, et al.. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet2017;390:2790–2802.
BorchmannP, GoergenH, KobeC, . PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017;390:2790–2802.10.1016/S0140-6736(17)32134-7)| false
CardeP, KarraschM, FortpiedC, et al.. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score ≥3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup trial. J Clin Oncol2016;34:2028–2036.
CardeP, KarraschM, FortpiedC, . Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, International Prognostic Score ≥3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup trial. J Clin Oncol 2016;34:2028–2036.10.1200/JCO.2015.64.5648)| false
FedericoM, LuminariS, IannittoE, et al.. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol2009;27:805–811.
FedericoM, LuminariS, IannittoE, . ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805–811.10.1200/JCO.2008.17.091019124807)| false
MounierN, BriceP, BolognaS, et al.. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol2014;25:1622–1628.
MounierN, BriceP, BolognaS, . ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014;25:1622–1628.10.1093/annonc/mdu189)| false
ConnorsJM, JurczakW, StrausDJ, . Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med 2018;378:331–344.2922450210.1056/NEJMoa1708984)| false
RamchandrenR, AdvaniRH, AnsellSM, et al.. Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma. Clin Cancer Res2019;25:1718–1726.
RamchandrenR, AdvaniRH, AnsellSM, . Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma. Clin Cancer Res 2019;25:1718–1726.3061713010.1158/1078-0432.CCR-18-2435)| false
JohnsonPW, SydesMR, HancockBW, et al.. Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol2010;28:3352–3359.
JagadeeshD, DiefenbachC, EvensAM. XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. Hematol Oncol2013; 31(S1, Suppl 1)69–75.
EvensAM, SweetenhamJW, HorningSJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park)2008;22:1369–1379.
EvensAM, SweetenhamJW, HorningSJ. Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park) 2008;22:1369–1379.19086599)| false
BallovaV, RüfferJU, HaverkampH, et al.. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol2005;16:124–131.
BallovaV, RüfferJU, HaverkampH, . A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005;16:124–131.10.1093/annonc/mdi023)| false
BöllB, GörgenH, FuchsM, et al.. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol2013;31:1522–1529.
BöllB, GörgenH, FuchsM, . ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 2013;31:1522–1529.10.1200/JCO.2012.45.4181)| false
EvensAM, HongF, GordonLI, et al.. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol2013;161:76–86.
EvensAM, HongF, GordonLI, . The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 2013;161:76–86.10.1111/bjh.12222)| false
HalbsguthTV, NogováL, MuellerH, et al.. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood2010;116:2026–2032.
HalbsguthTV, NogováL, MuellerH, . Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 2010;116:2026–2032.10.1182/blood-2009-11-253211)| false
BöllB, GoergenH, BehringerK, et al.. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood2016;127:2189–2192.
BöllB, GoergenH, BehringerK, . Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016;127:2189–2192.10.1182/blood-2015-11-681064)| false
StamatoullasA, BriceP, BouabdallahR, et al.. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol2015;170:179–184.
StamatoullasA, BriceP, BouabdallahR, . Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 2015;170:179–184.2589177710.1111/bjh.13419)| false
AndersenMD, KamperP, d’AmoreA, et al.. The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor †. Leuk Lymphoma2019;60:927–933.
AndersenMD, KamperP, d’AmoreA, . The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor †. Leuk Lymphoma 2019;60:927–933.3027712010.1080/10428194.2018.1515939)| false
SunH, AtenafuE, TsangR, et al.. Incidence and predictors of bleomycin pulmonary toxicity in Hodgkin lymphoma (HL) patients treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Blood2011;118:3643.
EvensAM, AdvaniRH, HelenowskiIB, et al.. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol2018;36:3015–3022.
EvensAM, AdvaniRH, HelenowskiIB, . Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol 2018;36:3015–3022.10.1200/JCO.2018.79.013930179569)| false
KolstadA, NomeO, DelabieJ, . Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma. Leuk Lymphoma 2007;48:570–576.1745460110.1080/10428190601126610)| false
FriedbergJW, Forero-TorresA, BordoniRE, et al.. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood2017;130:2829–2837.
FriedbergJW, Forero-TorresA, BordoniRE, . Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood 2017;130:2829–2837.10.1182/blood-2017-06-787200)| false
FriedbergJW, Forero-TorresA, HolkovaB, et al.. Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma. J Clin Oncol2018;36(15_suppl):7542.
FriedbergJW, Forero-TorresA, HolkovaB, . Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma. J Clin Oncol 2018;36(15_suppl):7542.10.1200/JCO.2018.36.15_suppl.7542)| false
LevisA, AnselmoAP, AmbrosettiA, et al..Intergruppo Italiano Linfomi (IIL). VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol2004;15:123–128.
LevisA, AnselmoAP, AmbrosettiA, .Intergruppo Italiano Linfomi (IIL). VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 2004;15:123–128.10.1093/annonc/mdh01214679131)| false
ProctorSJ, WilkinsonJ, JonesG, et al.. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood2012;119:6005–6015.
ProctorSJ, WilkinsonJ, JonesG, . Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 2012;119:6005–6015.10.1182/blood-2011-12-39655622577177)| false
BöllB, BredenfeldH, GörgenH, et al.. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood2011;118:6292–6298.
BöllB, BredenfeldH, GörgenH, . Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 2011;118:6292–6298.2191775910.1182/blood-2011-07-368167)| false
LinchDC, WinfieldD, GoldstoneAH, et al.. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet1993;341:1051–1054.
LinchDC, WinfieldD, GoldstoneAH, . Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993;341:1051–1054.10.1016/0140-6736(93)92411-L8096958)| false
MoskowitzCH, KewalramaniT, NimerSD, et al.. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol2004;124:645–652.
SirohiB, CunninghamD, PowlesR, et al.. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol2008;19:1312–1319.
SirohiB, CunninghamD, PowlesR, . Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 2008;19:1312–1319.1835613910.1093/annonc/mdn052)| false
BriceP, BouabdallahR, MoreauP, et al.. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant1997;20:21–26.
BriceP, BouabdallahR, MoreauP, . Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant 1997;20:21–26.10.1038/sj.bmt.17008389232251)| false
MoskowitzCH, NimerSD, ZelenetzAD, et al.. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood2001;97:616–623.
MoskowitzCH, NimerSD, ZelenetzAD, . A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616–623.10.1182/blood.V97.3.61611157476)| false
MoskowitzCH, YahalomJ, ZelenetzAD, et al.. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol2010;148:890–897.
MoskowitzCH, YahalomJ, ZelenetzAD, . High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010;148:890–897.10.1111/j.1365-2141.2009.08037.x20085577)| false
JostingA, FranklinJ, MayM, et al.. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol2002;20:221–230.
JostingA, FranklinJ, MayM, . New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 2002;20:221–230.)| false
SuredaA, ConstansM, IriondoA, et al.. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol2005;16:625–633.
SuredaA, ConstansM, IriondoA, . Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 2005;16:625–633.1573798610.1093/annonc/mdi119)| false
StiffPJ, UngerJM, FormanSJ, et al.. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant2003;9:529–539.
StiffPJ, UngerJM, FormanSJ, . The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003;9:529–539.10.1016/S1083-8791(03)00205-2)| false
WheelerC, EickhoffC, EliasA, et al.. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin’s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant1997;3:98–106.
WheelerC, EickhoffC, EliasA, . High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin’s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997;3:98–106.9267670)| false
HorningSJ, ChaoNJ, NegrinRS, et al.. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood1997;89:801–813.
HorningSJ, ChaoNJ, NegrinRS, . High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801–813.10.1182/blood.V89.3.8019028311)| false
SmeltzerJP, CashenAF, ZhangQ, et al.. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant2011;17:1646–1652.
MoskowitzCH, MatasarMJ, ZelenetzAD, et al.. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood2012;119:1665–1670.
AbaliH, UrünY, OksüzoğluB, et al.. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest2008;26:401–406.
AbaliH, UrünY, OksüzoğluB, . Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26:401–406.1844396110.1080/07357900701788098)| false
AparicioJ, SeguraA, GarceráS, . ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol 1999;10:593–595.10.1023/A:102645483134010416011)| false
ColwillR, CrumpM, CoutureF, et al.. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol1995;13:396–402.
ColwillR, CrumpM, CoutureF, . Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396–402.784460010.1200/JCO.1995.13.2.396)| false
JostingA, RudolphC, ReiserM, et al.. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol2002;13:1628–1635.
JostingA, RudolphC, ReiserM, . Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol 2002;13:1628–1635.10.1093/annonc/mdf22112377653)| false
LabradorJ, Cabrero-CalvoM, Pérez-LópezE, . ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma. Ann Hematol 2014;93:1745–1753.2486369210.1007/s00277-014-2114-0)| false
MartínA, Fernández-JiménezMC, CaballeroMD, et al.. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. Br J Haematol2001;113:161–171.
MartínA, Fernández-JiménezMC, CaballeroMD, . Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. Br J Haematol 2001;113:161–171.1132829610.1046/j.1365-2141.2001.02714.x)| false
RodriguezMA, CabanillasFC, HagemeisterFB, et al.. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol1995;6:609–611.
RodriguezMA, CabanillasFC, HagemeisterFB, . A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 1995;6:609–611.10.1093/oxfordjournals.annonc.a0592528573542)| false
BartlettNL, NiedzwieckiD, JohnsonJL, et al.. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol2007;18:1071–1079.
SantoroA, MagagnoliM, SpinaM, et al.. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica2007;92:35–41.
SantoroA, MagagnoliM, SpinaM, . Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 2007;92:35–41.10.3324/haematol.1066117229633)| false
CrumpM, KuruvillaJ, CoubanS, et al.. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol2014;32:3490–3496.
CrumpM, KuruvillaJ, CoubanS, . Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:3490–3496.10.1200/JCO.2013.53.959325267740)| false
GopalAK, PressOW, ShustovAR, et al.. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma2010;51:1523–1529.
GopalAK, PressOW, ShustovAR, . Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:1523–1529.10.3109/10428194.2010.491137)| false
GutierrezA, RodriguezJ, Martinez-SerraJ, et al.. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. OncoTargets Ther2014;7:2093–2100.
GutierrezA, RodriguezJ, Martinez-SerraJ, . Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. OncoTargets Ther 2014;7:2093–2100.10.2147/OTT.S70264)| false
MoskowitzAJ, HamlinPA, Jr., PeralesM-A, et al.. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol2013;31:456–460.
MoskowitzAJ, HamlinPA, Jr., PeralesM-A, . Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456–460.10.1200/JCO.2012.45.330823248254)| false
FehnigerTA, LarsonS, TrinkausK, et al.. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood2011;118:5119–5125.
FehnigerTA, LarsonS, TrinkausK, . A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119–5125.10.1182/blood-2011-07-36247521937701)| false
JohnstonPB, InwardsDJ, ColganJP, et al.. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol2010;85:320–324.
JohnstonPB, InwardsDJ, ColganJP, . A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320–324.20229590)| false
SantoroA, MazzaR, PulsoniA, et al.. Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study. J Clin Oncol2016;34:3293–3299.
SantoroA, MazzaR, PulsoniA, . Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study. J Clin Oncol 2016;34:3293–3299.10.1200/JCO.2016.66.446627382096)| false
BuddeLE, WuD, MartinDB, et al.. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol2018;183:601–607.
YounesA, GopalAK, SmithSE, et al.. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol2012;30:2183–2189.
YounesA, GopalAK, SmithSE, . Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 2012;30:2183–2189.2245442110.1200/JCO.2011.38.0410)| false
GopalAK, ChenR, SmithSE, et al.. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood2015;125:1236–1243.
GopalAK, ChenR, SmithSE, . Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125:1236–1243.10.1182/blood-2014-08-595801)| false
MoskowitzAJ, SchöderH, YahalomJ, et al.. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol2015;16:284–292.
MoskowitzAJ, SchöderH, YahalomJ, . PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015;16:284–292.2568384610.1016/S1470-2045(15)70013-6)| false
ChenR, PalmerJM, MartinP, et al.. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant2015;21:2136–2140.
ChenR, PalmerJM, MartinP, . Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2015;21:2136–2140.10.1016/j.bbmt.2015.07.01826211987)| false
Garcia-SanzR, SuredaA, Alonso-AlvarezS, et al.. Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood2015;126:582.
Garcia-SanzR, SuredaA, Alonso-AlvarezS, . Evaluation of the regimen brentuximab vedotin plus ESHAP (BRESHAP) in refractory or relapsed Hodgkin lymphoma patients: preliminary results of a phase I-II trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood 2015;126:582.10.1182/blood.V126.23.582.582)| false
LaCasceAS, BociekG, SawasA, et al.. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood2015;126:3982.
LaCasceAS, BociekG, SawasA, . Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood 2015;126:3982.10.1182/blood.V126.23.3982.3982)| false
O’ConnorOA, LueJK, SawasA, et al.. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol2018;19:257–266.
HerreraAF, MoskowitzAJ, BartlettNL, et al.. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood2018;131:1183–1194.
HerreraAF, MoskowitzAJ, BartlettNL, . Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 2018;131:1183–1194.10.1182/blood-2017-10-81122429229594)| false
HerreraAF, ManleyT, SacchiM, et al.. Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: Long-term follow-up results from the single-arm phase 1/2 study. Blood2019;134(Supplement_1):238.
MoskowitzCH, NademaneeA, MassziT, et al.. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2015;385:1853–1862.
MoskowitzCH, NademaneeA, MassziT, . Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385:1853–1862.10.1016/S0140-6736(15)60165-925796459)| false
AnsellSM, LesokhinAM, BorrelloI, . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311–319.10.1056/NEJMoa141108725482239)| false
ArmandP, EngertA, YounesA, et al.. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol2018;36:1428–1439.
ArmandP, ShippMA, RibragV, et al.. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol2016;34:3733–3739.
ChenR, ZinzaniPL, FanaleMA, et al.. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol2017;35:2125–2132.
ChenR, ZinzaniPL, FanaleMA, . Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125–2132.10.1200/JCO.2016.72.131628441111)| false
YounesA, SantoroA, ShippM, et al.. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol2016;17:1283–1294.
YounesA, SantoroA, ShippM, . Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283–1294.2745139010.1016/S1470-2045(16)30167-X)| false
JostingA, NogováL, FranklinJ, et al.. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol2005;23:1522–1529.
JostingA, NogováL, FranklinJ, . Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 2005;23:1522–1529.10.1200/JCO.2005.05.022)| false
ConstineLS, YahalomJ, NgAK, et al.. The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys2018;100:1100–1118.
ConstineLS, YahalomJ, NgAK, . The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2018;100:1100–1118.10.1016/j.ijrobp.2018.01.01129722655)| false
EvensAM, AltmanJK, MittalBB, et al.. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin’s lymphoma. Ann Oncol2007;18:679–688.
EvensAM, AltmanJK, MittalBB, . Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin’s lymphoma. Ann Oncol 2007;18:679–688.10.1093/annonc/mdl49617307757)| false
Fernández de LarreaC, MartínezC, GayaA, et al.. Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Ann Oncol2010;21:1211–1216.
Fernández de LarreaC, MartínezC, GayaA, . Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation. Ann Oncol 2010;21:1211–1216.10.1093/annonc/mdp487)| false
AlvarezI, SuredaA, CaballeroMD, et al.. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant2006;12:172–183.
SuredaA, CanalsC, ArranzR, et al.. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica2012;97:310–317.
SuredaA, CanalsC, ArranzR, . Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310–317.)| false
CastagnaL, BramantiS, DevillierR, et al.. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplant2017;52:683–688; erratum in: Bone Marrow Transplant 2017;52:797.
BöllB, GoergenH, ArndtN, et al.. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol2013;31:4431–4437.
BöllB, GoergenH, ArndtN, . Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol 2013;31:4431–4437.10.1200/JCO.2013.49.8246)| false
ChenRW, PalmerJ, MartinP, et al.. Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. Blood2014;124:501.
ChenRW, PalmerJ, MartinP, . Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. Blood 2014;124:501.10.1182/blood.V124.21.501.501)| false
